ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Tesaro, MD Anderson target small molecules

by Ann M. Thayer
April 4, 2016 | APPEARED IN VOLUME 94, ISSUE 14

Biopharmaceutical developer Tesaro and the Institute for Applied Cancer Science (IACS) at the University of Texas MD Anderson Cancer Center will work together to discover and develop drug candidates against immuno-oncology targets. The collaboration is the first for IACS focused on small molecules. IACS will conduct drug discovery research and identify clinical candidates. Tesaro will fund R&D in return for exclusive rights to develop and commercialize any candidates that emerge.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment